Full Text View
Tabular View
No Study Results Posted
Related Studies
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
This study is ongoing, but not recruiting participants.
Study NCT00143741   Information provided by University of Chicago
First Received: September 1, 2005   Last Updated: January 28, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
End-Stage Kidney Disease
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
More general conditions related to this trial
Kidney Failure
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
Atorvastatin (Lipitor)
Additional drug interventions recognized in this trial
Atorvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antilipemic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Chicago


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services